TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Internalized behavior assessment system score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Threshold dose changes (TDCs) for objective symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threshold dose changes (TDCs) for subjective symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-A total score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-Bil concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of treated rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median intravenous dose of methyl‐prednisolone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rejection-free biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sum of target lesion diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of late incisional hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Post-test scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: levels of depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in conspicuity of the common bile duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Contrast-to-noise ratios improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1st analgesic requirement in the postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with high-quality transitions home
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Return to the emergency department within 3 days of discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of readmission at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in body fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CD68+ macrophage staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the blood-glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall knowledge score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: precautionary behavior
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Reduction in ocular symptoms of AR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of rTOSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response achievement
Endpoint domain: Life impact
Endpoint subdomain: Daily living activities
Primary endpoint: anti-merozoite antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GIA (Growth Inhibition Assay)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative blood creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative urea levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cardiac output (CO) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean days of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: JSE score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: levels of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amygdala-vlPFC connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental mental well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median Tfirst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delay in transit of semi-solids into the infraband compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: C reactive protein (CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glove perforation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperhidrosis Disease Severity Scale responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in sweat production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index improvements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative vasopressor requirements 24 hours after induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of relative adrenocortical insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: high-confident incorrect responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postcontrast ultrasound inter-reviewer agreement for detection of tumor margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postcontrast ultrasound inter-reviewer agreement for local tumor invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postcontrast ultrasound inter-reviewer agreement for adenopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular dysfunction prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psoriasis Area and Severity Index 90 and 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Physician's Global Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Affected body surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F&V purchases (kg per household/2 wk)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants consuming recommended F&Vs (≥400 g/d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac index at T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma TxB2, PGI, LTC4D4E4, TNF, and IL‐6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma IL‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCT utilization among men
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with participation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Productivity outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Community activity outcomes
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Self-reported compliance with referrals and recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentrations of serum folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Basal levels of total T3 (T3T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Basal levels of free T3 (T3F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Blunted TSH response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Presence of larvae or pupae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VAS score of arthralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PKE ROM (Passive Knee Extension Range of Motion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak torque deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean aqueous level of levofloxacin and moxifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local regional recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: reductions in overall psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less frequent illicit drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Air-Bone Gap (ABG) after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: good outcomes at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ED50 of ropivacaine compared to bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of renal replacement therapy or death
Endpoint domain: Mortality/survival
Primary endpoint: hand strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actuarial graft survival at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Cytokine nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bioavailable Te secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Leydig cell responsivity to LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative incidence of GDM
Endpoint domain: Mortality/survival
Primary endpoint: 15D scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Classification of affect display in faces with lesions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for rivastigmine patch over capsule
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with administration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interference with daily life
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: reduced stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of sexual dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in patient comprehension scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Modified Ashworth scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ankle passive range of motion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Freedom from AF at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cessation of fever within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in average monthly seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in seizure severity based on parental global evaluations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with a > or = 50% reduction in major seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sustained loss of HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of M-CHAT-R/F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of M-CHAT-R/F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of M-CHAT-R/F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superselective embolization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of esophageal injury
Endpoint domain: Adverse events/effects
Primary endpoint: PDSS total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cue‐provoked craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in morbi-mortality in patients infected by HIV
Endpoint domain: Mortality/survival
Primary endpoint: Antiretroviral efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Good tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: freedom from seizures
Endpoint domain: Mortality/survival
Primary endpoint: Hague Seizure Severity scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pediatric Quality of Life Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MiL fulfillment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Importance ascribed to meaning framework
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional remission
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Relapse-free period
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gingival Index (GI) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response rates at LOQ of 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates at LOQ of 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of HBV reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of children seropositive to at least 1 vaccine antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Venous Clinical Severity Score (VCSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aberdeen Varicose Vein Questionnaire (AVVQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Requirement for subsequent interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Non-fatal heart attacks, strokes and revascularisation procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: physiologic dead space ventilation (VD/VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to starting compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of timely interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bifidobacterium and Prevotella amounts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPS concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in premenstrual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS scores in function in sports and recreational activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean manual maximum side‐to‐side difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in dyschromia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in rhytid scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contralateral breast dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiation outcomes
Primary endpoint: quit-day craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of IL-10 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase of natural killer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase of CD8+ T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: survival of intensive care unit patients
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative LVM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PSEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depression symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean ALT at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Improvement in SBU scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBU prevalence of 'always'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicular fluid levels of LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Follicular fluid levels of FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Follicular fluid concentration of progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: impulsive decision making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cumulative incidence of HIV-1 infection at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: Atrial Tachycardia (AT) burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attack rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge level improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to progression (TIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of anginal episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weekly nitroglycerin tablet consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality in CHF patients
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalization due to CHF
Endpoint domain: Mortality/survival
Primary endpoint: Oxygen saving benefit ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nursing home placement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Therapeutic dose identification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: midazolam AUC0‐12h decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum excursion of knee abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: eccentric hip abductor torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: triple hop test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Noninferiority of MGS implantation compared to MT pretreatment followed by BMS deployment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical intelligence level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastrointestinal haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes